Incidental prostate cancer in transurethral resection specimens. Pathological anatomy service CMDLT period 2020 – 2024
DOI:
https://doi.org/10.55361/cmdlt.v19iSuplemento.654Keywords:
Incidental cancer, Transurethral resection, Prostate adenocarcinomaAbstract
Prostate cancer is a frequent malignant neoplasm globally, with limitations in timely diagnosis. OBJECTIVES: To determine the frequency of incidental prostate cancer in biopsy results obtained through TURP with a clinical diagnosis of prostatic hyperplasia. METHODS: A descriptive, retrospective, and cross-sectional study was conducted, based on the review of biopsy reports obtained via the TURP procedure with a previous diagnosis of prostatic hyperplasia. Reports of specimens incidentally diagnosed with prostate adenocarcinoma for the period from January 2020 to December 2024 were collected. RESULTS: A total of 93 TURP biopsy reports were obtained from patients with an age range of 45 to 89 years and a mean age of 66.9 years, all with a previous diagnosis of prostatic hyperplasia. Of these patients, 7 were incidentally diagnosed with acinar type histological prostate adenocarcinoma, which corresponds to 7,53%. CONCLUSIONS: The frequency of incidental prostate cancer detected in TURP specimens at the study center during the specified period is 7,53%. This finding underscores the importance of routine histopathological examination of the resected tissue, confirming that TURP, while not a primary diagnostic procedure, constitutes a relevant pathway for the incidental detection of this neoplasm in patients undergoing surgery for benign obstructive pathology. Due to these findings, the need for strict postoperative follow-up and for informing patients about the risk of incidentally identifying cancer in the anatomopathological study is emphasized incidental cancer, transurethral resection, prostate adenocarcinoma.
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Revista Científica CMDLT

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.



